Olivia Vizier

empowered

Developing Prophylactic Cancer Vaccine to Attack Breast Cancer and Other Solid Tumors with Amit Kumar Anixa Biosciences

Amit Kumar is the President and CEO of Anixa Biosciences and is working on a prophylactic vaccine to prevent the onset of breast cancer rather than a therapeutic vaccine to fight the solid tumors. Anixa is also working on CAR-T therapy for solid tumors and using artificial intelligence and machine learning to discover compounds to treat

Developing Prophylactic Cancer Vaccine to Attack Breast Cancer and Other Solid Tumors with Amit Kumar Anixa Biosciences Read More »

biospace

A Perfect Storm of Superbugs

Recce’s lead drug candidate, called R327, is a synthetic polymer that is currently undergoing Phase I trials for sepsis, with an ongoing Phase I/II trial for burn wound infections. According to Graham, R327 utilizes multiple inhibitory mechanisms that work in “a synergistic compounding fashion.” These mechanisms include adenosine triphosphate (ATP) inhibition, cell membrane permeabilization and

A Perfect Storm of Superbugs Read More »

cell gene

Harnessing The Human Virome For The Next Generation Of Gene Therapy Vectors

Ring’s research team has uncovered and characterized the world’s largest collection of commensal anelloviruses and is harnessing those best suited for specifically targeting a wide array of diseases with significant unmet needs. The unique biology of anelloviruses may indeed provide a foundation for an unparalleled new gene therapy platform and the resulting new class of

Harnessing The Human Virome For The Next Generation Of Gene Therapy Vectors Read More »

biospace

Incoming CEO Andy Kidd Prepares to Take Aptinyx to the Next Level

As 2022 begins, Aptinyx is laying the groundwork to transition to a late-stage clinical, and one day commercial, company. At the same time, its senior leadership also is transitioning into new roles. Andy Kidd, M.D., takes on the role of CEO after stints as Aptinyx’s president and chief operating officer, and before that, chief commercial officer. Norbert

Incoming CEO Andy Kidd Prepares to Take Aptinyx to the Next Level Read More »

endpoints

Sotio partners with Merck to test lead candidate with Keytruda; DC’s KeifeRx raises $6M in Series A — and brings on two new board members

Sotio has been on a roll lately. The quiet Czech biotech based in Prague got a massive $315 million raise last week, and now the biotech announced today that it’s joined in on a collaboration with Merck to evaluate a combo of Sotio’s lead candidate SOT101 with Merck’s PD-1 antibody Keytruda.

Sotio partners with Merck to test lead candidate with Keytruda; DC’s KeifeRx raises $6M in Series A — and brings on two new board members Read More »

Fierce-Biotech

Little European biotech Sotio nabs a super $316M funding round for its superagonist work

Sotio is also working on earlier efforts, including BOXR1030, its next-gen CAR-T program for solid tumors expressing GPC3 and based on its so-called BOXR platform “that aims to enhance the fitness of T cells in the hostile tumor microenvironment,” according to the Prague-based company.

Little European biotech Sotio nabs a super $316M funding round for its superagonist work Read More »